Evidence map›Paper›PMID 39136906›Full record

ArticleMolecular neurobiology2025

Selegiline Improves Cognitive Impairment in the Rat Model of Alzheimer's Disease.

Hamid Shokati Basir, Naser Mirazi, Alireza Komaki, Behnam Mohamadpour, Abdolkarim Hosseini

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Unveiling the pathogenesis and therapeutic strategies of Alzheimer's disease through cuproptosis.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hamid Shokati BasirDepartment of Biology, Faculty of Basic Science, Bu-Ali Sina University, Hamedan, Iran.
Naser MiraziDepartment of Biology, Faculty of Basic Science, Bu-Ali Sina University, Hamedan, Iran. mirazi205@gmail.com.
Alireza KomakiDepartment of Neuroscience, School of Science and Advanced Technologies in Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Behnam MohamadpourDepartment of Biology, Faculty of Basic Science, Bu-Ali Sina University, Hamedan, Iran.
Abdolkarim HosseiniDepartment of Animal Sciences and Marine Biology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a progressive neurological disorder characterized by cognitive decline. This study was undertaken to evaluate the effects of selegiline (SEL) against AD-induced cognitive deficits and explore the possible involved mechanisms. AD was induced by unilateral intracerebroventricular (U-ICV) injection of 5 μg of amyloid beta

Indexed as

Alzheimer DiseaseCognitive DysfunctionSelegilineAmyloid beta-PeptidesAnimalsDisease Models, AnimalHippocampusLong-Term PotentiationMaleMaze LearningOxidative StressPeptide FragmentsRatsRats, WistarAmyloid beta-PeptidesPeptide FragmentsSelegilineAlzheimer’s diseaseLong-term potentiationOxidative stressSelegilineSpatial memory

Identifiers

PMID39136906

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.